Home

Intellia Therapeutics, Inc. - Common Stock (NTLA)

6.8700
-0.5800 (-7.79%)
NASDAQ · Last Trade: May 31st, 8:57 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close7.450
Open7.430
Bid6.970
Ask7.000
Day's Range6.830 - 7.430
52 Week Range5.900 - 28.18
Volume8,853,703
Market Cap605.53M
PE Ratio (TTM)-1.316
EPS (TTM)-5.2
Dividend & YieldN/A (N/A)
1 Month Average Volume3,599,357

Chart

About Intellia Therapeutics, Inc. - Common Stock (NTLA)

Intellia Therapeutics is a biotechnology company focused on developing innovative gene-editing therapies to treat serious genetic diseases. The company leverages its proprietary CRISPR/Cas9 technology platform to create precise and effective treatments that have the potential to address the root causes of diseases. By advancing its research and clinical programs, Intellia aims to pioneer new therapeutic approaches that could significantly improve patient outcomes and transform the landscape of genetic medicine. Read More

News & Press Releases

Cathie Wood's Ark Invest Continues To Offload Tesla As Elon Musk Moves On From Trump Administrationbenzinga.com
Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.
Via Benzinga · May 30, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · May 29, 2025
Keep an eye on the top gainers and losers in Thursday's session.chartmill.com
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · May 29, 2025
Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dipstocktwits.com
The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.
Via Stocktwits · May 29, 2025
Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviewsbenzinga.com
Via Benzinga · May 29, 2025
Earnings Scheduled For May 8, 2025benzinga.com
Via Benzinga · May 8, 2025
A Glimpse of Intellia Therapeutics's Earnings Potentialbenzinga.com
Via Benzinga · May 7, 2025
Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Coursebenzinga.com
Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.
Via Benzinga · May 29, 2025
The market is filled with gapping stocks in Thursday's session.chartmill.com
Today's session on Thursday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · May 29, 2025
HP Posts Downbeat Earnings, Joins SentinelOne, Best Buy And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 29, 2025
What's going on in today's pre-market sessionchartmill.com
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
Via Chartmill · May 29, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 29, 2025
Why Nvidia Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · May 29, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · May 28, 2025
Analysts Think These Stocks Could More Than Double in Value
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Via MarketBeat · May 23, 2025
INTELLIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Intellia Therapeutics, Inc. (NASDAQ:NTLA) on behalf of long-term stockholders following a class action complaint that was filed against Intellia on February 11, 2025 with a Class Period from July 30, 2024 to January 8, 2025. Our investigation concerns whether the board of directors of Intellia have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · May 22, 2025
Forecasting The Future: 11 Analyst Projections For Intellia Therapeuticsbenzinga.com
Via Benzinga · May 12, 2025
Marriott International To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Mondaybenzinga.com
Via Benzinga · May 12, 2025
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Boughtfool.com
The popular growth investor keeps adding to some of her favorite stocks.
Via The Motley Fool · April 30, 2025
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platformsbenzinga.com
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details.
Via Benzinga · April 26, 2025
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boostinvestors.com
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Via Investor's Business Daily · April 21, 2025
Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Mondaybenzinga.com
Via Benzinga · April 21, 2025
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Intellia Therapeutics, Inc. (“Intellia” or “the Company”) (NASDAQ: NTLA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · April 14, 2025
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA) and reminds investors of the April 14, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · April 14, 2025
NTLA Investors Have the Opportunity to Lead the Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · April 13, 2025